Table 1. Principle characteristics of the studies included in the Meta-Analysis for SNPs at NUDT15 rs116855232 locus.
| Year | Author [*] | Ethnicity | Sample sizea | Genotype counts (case) | Genotype counts (control) | AZA dose (mg/m2) (mean ± SD) (normalized dose)b | Diseases | Type of study | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Control | TT | CT | CC | TT | CT | CC | TT | CT | CC | |||||
| 2014 | Suk-Kyun Yang [2] | Korean | 346 | 632 | 14 | 133 | 199 | 0 | 43 | 589 | 2.335 ± 0.485 (0.522 ± 0.108) | 3.697 ± 2.145 (0.827 ± 0.480) | 4.472 ± 2.436 (1 ± 0.545) | IBD | myelotoxicity susceptibility and intolerance dose |
| 2015 | Y Kakuta [22] | Japanese | 34 | 101 | 5 | 10 | 19 | 0 | 13 | 88 | NA | 1.613 ± 0.891 (0.557 ± 0.307) | 2.915 ± 1.203 (1 ± 0.413) | IBD | myelotoxicity susceptibility and intolerance dose |
| 2016 | Ayumi Asada [21] | Japanese | 45 | 116 | 2 | 18 | 25 | 0 | 14 | 102 | 2.12 (0.872) | 2.26 ± 1.130 (0.930 ± 0.465) | 2.43 ± 1.270 (1 ± 0.523) | IBD | myelotoxicity susceptibility and intolerance dose |
| 2016 | X. Zhu [27] | Chinese Han | 65 | 188 | 4 | 36 | 25 | 0 | 17 | 171 | NA | NA | NA | IBD | myelotoxicity susceptibility |
| 2016 | Swarup A. V. Shah [25] | Indian | 6 | 63 | 1 | 5 | 0 | 0 | 3 | 60 | 2.066 ± 0.566 (0.723 ± 0.198) | 2.858 ± 0.566 (1 ± 0.198) | IBD | intolerance dose | |
| 2015 | Jun J. Yang [12] | East Asian | 61 | NA | 1 | 10 | 50 | NA | NA | NA | 10.125 (0.169) | 35.55 ± 11.25 (0.594 ± 0.188) | 59.85 ± 17.85 (1 ± 0.298) | ALL | intolerance dose |
| Hispanic | 222 | NA | 1 | 16 | 205 | NA | NA | NA | 2.175 (0.033) | 52.425 ± 13.4 (0.796 ± 0.355) | 65.85 ± 16.65 (1 ± 0.253 ) | ||||
| Other | 380 | NA | 0 | 5 | 375 | NA | NA | NA | NA | 59.475 ± 13.95 (0.924 ± 0.217) | 64.35 ± 17.55 (1 ± 0.273) | ||||
| 2015 | Yoichi Tanaka [14] | Japanese | 38 | 54 | 5 | 13 | 20 | 1 | 5 | 48 | NA | NA | NA | ALL | myelotoxicity susceptibility |
| 2015 | D-C Liang [23] | Taiwan Chinese | 310 | NA | 2 | 70 | 238 | NA | NA | NA | 18.8 ± 7.4 (0.213 ± 0.084) | 61.4 ± 23.4 (0.696 ± 0.265) | 88.2 ± 30.6 (1 ± 0.347) | ALL | intolerance dose |
| 2016 | Kanhatai Chiengthong [28] | Thai | 28 | 54 | 1 | 9 | 18 | 1 | 1 | 52 | 54.608 ± 8.719 (0.631 ± 0.101) | 86.542 ± 9.525 (1 ± 0.110) | ALL | myelotoxicity susceptibility and intolerance dose | |
| 2016 | Takaya Moriyama [24] | Guatemala | 181 | NA | 1 | 18 | 162 | NA | NA | NA | 8.944 (0.128) | 54.954 ± 34.516 (0.789 ± 0.496) | 69.638 ± 30.261 (1 ± 0.435) | ALL | intolerance dose |
| Singaporean | 83 | NA | 1 | 17 | 65 | NA | NA | NA | 5.522 (0.06) | 65.894 ± 25.765 (0.721 ± 0.282) | 91.354 ± 27.674 (1 ± 0.303) | ||||
| Japanese | 32 | NA | 1 | 9 | 22 | NA | NA | NA | 5.013 (0.05) | 69.950 ± 28.912 (0.702 ± 0.290) | 99.674 ± 34.231 (1 ± 0.343) | ||||
| 2016 | Hisato Suzuki [26] | Japanese | 46 | 5 | 0 | 10 | 36 | 0 | 0 | 5 | NA | 59.946 ± 16.405 (0.913 ± 0.250) | 65.647 ± 23.887 (1 ± 0.364) | ALL | myelotoxicity susceptibility and intolerance dose |
aCase and Control indicates patients with or without thiopurines-induced myelotoxicity, respectively;
b6-MP dose was converted to AZA equivalent dose using a conversion factor of 2.08, Meeh-Rubner formula was used to unify the units into mg/m2, AZA dose of each genotype was also normalized against CC (wildtype) ;
*numbers in the brackets represent the references in the manuscript
NA: not available.